Klivira
Request demo

Streamlining Xolair Prior Authorization for Gastroenterology Practices

Navigating Xolair prior authorization for gastroenterology patients, especially those with co-morbid conditions, presents unique administrative challenges. Klivira's platform automates the intricate process, ensuring timely approvals and reduced administrative burden.

Gastroenterology practices face a substantial prior authorization (PA) burden, particularly with high-cost biologics, specialized procedures, and advanced imaging. While Xolair (omalizumab) is not a primary GI therapeutic, patients with co-occurring conditions like severe asthma or chronic urticaria may require its use, necessitating efficient PA management within a GI practice workflow. Klivira provides a comprehensive solution to manage all PA requirements, regardless of drug or indication.

The Landscape of Prior Authorization in Gastroenterology

Gastroenterology is a specialty heavily impacted by prior authorization, with significant volume concentrated in chronic conditions requiring biologics and advanced diagnostics. Managing these PAs efficiently is critical for patient access and revenue cycle stability, encompassing a broad range of high-volume categories.

High-Volume PA Categories for GI Practices

  • IBD biologics (e.g., TNF inhibitors, integrin inhibitors, IL-12/23 inhibitors)
  • Hepatitis C direct-acting antivirals
  • Advanced imaging (e.g., MRCP, MR enterography, CT enterography)
  • Endoscopic procedures with specific PA requirements (e.g., capsule endoscopy, ERCP, EUS)
  • Specialty drugs for functional GI disorders

Addressing Xolair Prior Authorization in a GI Setting

While Xolair (omalizumab) is primarily indicated for conditions like severe persistent asthma, chronic idiopathic urticaria, and nasal polyps, GI practices may encounter its prior authorization for patients with co-morbidities. Klivira's platform is designed to manage PAs for any prescribed medication, seamlessly integrating with EMRs to gather necessary clinical documentation, regardless of the drug's primary specialty.

Key Documentation for Biologic Prior Authorizations

Effective prior authorization for biologics, including Xolair or IBD treatments, hinges on comprehensive documentation. Payers typically require specific clinical evidence to approve these high-cost therapies, often aligning with established clinical guidelines from bodies like ACG or AGA for GI-specific biologics. Klivira helps aggregate and submit these crucial data points.

Common Documentation Requirements for Biologics

  • Diagnosis confirmation and disease severity assessment (e.g., Mayo score for UC, CDAI for Crohn's)
  • Documentation of prior conventional therapy trials or biologic experience
  • Required pre-initiation screenings (e.g., TB, hepatitis) and their results
  • Clinical rationale for advanced imaging or specialized procedures
  • Adherence to payer-specific medical necessity criteria and step therapy protocols

Klivira's Solution for Diverse Prior Authorization Needs

Klivira's platform provides a unified approach to prior authorization, capable of handling the specific demands of gastroenterology while also accommodating drugs like Xolair that may fall outside the core specialty. Our intelligent automation streamlines workflows, from initial submission to re-authorization, reducing manual effort and improving approval rates across your entire patient population.

Frequently asked questions

Why might a gastroenterology practice need to manage Xolair prior authorizations?

While Xolair (omalizumab) is not a primary GI therapeutic, patients receiving care in gastroenterology often have co-morbid conditions such as severe asthma or chronic urticaria. If a GI specialist is managing the overall care or prescribing for these co-existing conditions, they may need to process Xolair PAs. Klivira supports managing all such diverse prior authorization requirements.

How does Klivira handle step therapy requirements for biologics in GI?

Klivira's platform incorporates ACG/AGA-guideline-aware step therapy logic, automating the verification of prior conventional therapy trials or specific biologic sequencing required by payers for IBD biologics. This ensures submissions are compliant with payer policies, reducing denials related to step therapy.

Does Klivira integrate with our EMR to pull necessary documentation for GI PAs?

Yes, Klivira offers robust EMR integration capabilities, including SMART on FHIR, to automatically extract relevant patient data, medication history, and diagnostic results. This significantly reduces the manual effort required to compile documentation for prior authorization submissions for both GI-specific drugs and others like Xolair.

Can Klivira manage re-authorizations for chronic GI conditions?

Absolutely. For chronic GI conditions like IBD, which often require periodic re-authorization for biologics, Klivira provides automated workflows. Our system tracks re-authorization timelines, prompts for necessary updated documentation, and facilitates timely resubmissions to ensure continuity of care.

What common denial reasons does Klivira help mitigate for GI practices?

Klivira addresses common denial reasons such as non-compliance with step therapy for IBD biologics, biosimilar substitution mandates, insufficient disease severity documentation (e.g., missing Mayo score), and gaps in pre-biologic screening. Our policy logic and documentation support help proactively prevent these issues.

Related coverage

Other xolair prior authorization by payer

Other xolair prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo